Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma

Table 1 Barcelona clinic liver cancer B sub-stage categories

	BCLC sub staging
	B1	B2	B3	B4
Child Pugh class	5-6-7	5-6	7	8-9
Beyond Milan and within up-to-7	In	Out	Out	Any
ECOG PS	0	0	0	0-1

BCLC: Barcelona clinic liver cancer; ECOG PS: The Eastern Cooperative Oncology Group performance status.

Table 2 Baseline and tumoral characteristics

Characteristics	B1	B2	B3	B4	P value1
Age (yr)	62	61	60	60	0.77
Gender (male,%)	66	73	76	50	0.48
Caucasians (%)	95	99	96	100	0.28
HCV positive (%)	81	77	76	100	0.79
Alcohol (%)	33	33	34	0	1.00
PS (0) (%)	100	95	95	50	0.27
AST (U/L)	35	36	37	38	0.90
ALT (U/L)	64	67	69	70	0.80
GGT (U/L)	133	136	144	155	0.79
Platelets (× 1000/UL)	110	110	105	90	0.35
PT (%)	73	73	77	79	0.72
Albumin (U/L)	3.5	3.4	3.3	3.3	0.28
BT (mg/dL)	1.2	1.3	1.3	1.4	0.22
Creatinine	0.93	0.94	0.95	0.97	0.73
No. of TAE session	1.7	1.9	1.9	1.9	0.20

¹P value analysis excluded B4 subgroup (only 2 patients). HCV: Hepatitis C virus; PS: Performance status; AST: Aspartate transaminase; ALT: Alanine transaminase; GGT: Gamma-glutamyl transferase; PT: Prothrombine time; BT: Total bilirubin; TAE: Transarterial embolization.

Table 3 Survival rates according to barcelona clinic liver cancer classification and subclassification

	n (%)	Mean survival rate (mo) (95%CI)
Overall	136 (100)	35.8 (25.0-52.0)
BCLC A	46 (33.7)	38.1 ( 25.0-52.0)
BCLC B	90 (66.2)	29.0 ( 17.2-34.3)
BCLC B1	48 (52.8)	33.6 ( 32.9-34.3)
BCLC B2	27 (30.2)	28.6 (27.5-29.8)
BCLC B3	13 (15.1)	19.0 ( 17.2-20.9)
BCLC B4	2 (1.9)	13.0 ( 25.0-52.0)

BCLC: Barcelona clinic liver cancer.

Table 4 Barcelona clinic liver cancer B substaging response rates according to mRECIST n (%)

	CR	PR	PD	SD
B1	12 (25)	29 (60.4)	3 (6.25)	3 (6.25)
B2	6 (22.2)	13 (48)	1 (3.7)	7 (26.1)
B3	1 (7.6)	4 (30.7)	1 (7.6)	7 (53.8)
B4	-	-	1 (50)	1 (50)

CR: Complete response; PR: Partial response; PD: Progressive disease; SD: Stable disease.